COMP <GO>
TEVA vs TAK // EV/EBITDA & P/E VALUATION
Teva Pharmaceutical Industries Limited (NYSE) VS. Takeda Pharmaceutical Company Limited American (NYSE) • 15-METRIC TALLY: TEVA 4
— TAK 8
▲ EV/EBITDA & P/E VALUATION LEADER: TEVA
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
valuation
20.8x
LAST: $20.91 (+4.50%) • MKT CAP: $63.23B
valuation
21.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TEVA VS. TAK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TEVA | TAK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 9.90% | -0.50 | TAK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.8x | 21.0x | -0.20 | TEVA | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 2.21% | -0.40 | TAK | /fcf-yield <GO> |
| Operating Margin | 12.50% | 13.90% | -1.40 | TAK | /operating-margins <GO> |
| Net Profit Margin | 8.20% | 10.90% | -2.70 | TAK | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | -3.30% | +7.60 | TEVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.02 | 3.74 | -2.72 | TAK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TEVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 56.6 | +2.00 | TEVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.06 | -0.06 | TAK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.9x | 30.5x | +1.40 | TAK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.32B | $63.23B | -$14.90B | TAK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TEVA REV | TAK REV | TEVA GROSS % | TAK GROSS % | TEVA FCF | TAK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | — | 51.8% | — | $872.4M | — |
| FY 2024 | $16.54B | — | 48.7% | — | $502.5M | — |
| FY 2023 | $15.85B | — | — | — | $654.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TEVA // BETA 1.00
TAK // BETA 1.06